title: Is maintenance antiparkinsonian treatment necessary?
abstract: The authors designed a three-phase prospective trial in which only those patients who developed an acute, neuroleptic-induced extrapyramidal side effect (EPSE) received benztropine (BZ) at 2 mg i.m. and then 1 mg p.o. b.i.d. for 2 days after their symptoms were rated for severity and type (Preparatory Phase 1). They were then randomly assigned under double-blind conditions to continue BZ or be switched to placebo for 8 days (Experimental Phase 2). Finally in Phase 3 (Followup), all patients continued on placebo in a single-blind design until Day 30. If the patient re-experienced an acute EPSE that was of sufficient severity to require immediate BZ administration, he or she was rated, treated, and then dropped from the study. EPSE scores and dropout rates did not differ in Phase 2 between the placebo- and BZ-treated groups. Implications for the continuation, cessation, or intermittent use of antiparkinsonian (AP) drugs are discussed.
authors.affiliation: Illinois State Psychiatric Institute, Chicago 60612.
authors.forename: J E
authors.initials: JE
authors.lastname: Comaty
authors.forename: P G
authors.initials: PG
authors.lastname: Janicak
authors.forename: J
authors.initials: J
authors.lastname: Rajaratnam
authors.forename: R P
authors.initials: RP
authors.lastname: Sharma
authors.forename: D
authors.initials: D
authors.lastname: Baker
authors.forename: J M
authors.initials: JM
authors.lastname: Davis
mesh_terms: D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D011618:Psychotic Disorders / Q000150:complications
chemical_list: D000978:Antiparkinson Agents; D014150:Antipsychotic Agents